CSIMarket Company Name, Ticker, Suppliers, else..
 
Brainsway Ltd   (NASDAQ: BWAY)
 
Price: $14.5200 $0.22 1.538%
Day's High: $14.670000076293945 Week Perf: 0.62 %
Day's Low: $ 14.19 30 Day Perf: -4.66 %
Volume (M): 80,928 52 Wk High: $ 17.40
Volume (M$): $ 0 52 Wk Avg: $12.07
Open: $14.42 52 Wk Low: $7.14



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 129
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) 8
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Brainsway Ltd is a medical technology company that specializes in developing and marketing non-invasive brain stimulation systems for the treatment of various neurological and psychiatric disorders. The company is known for its deep transcranial magnetic stimulation (dTMS) technology, which delivers magnetic fields to specific areas of the brain. Brainsway's products are used by healthcare professionals worldwide for conditions such as major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company aims to provide innovative and effective solutions to improve the quality of life for individuals suffering from these disorders.


   Company Address: 16 Hartum Street Jerusalem 9777516
   Company Phone Number: 2-582-4030   Stock Exchange / Ticker: NASDAQ BWAY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ECOR   -1.66%    
MDT   -2.42%    
NMTC   -20.56%    
SRTS        1.43% 
STIM   -1.73%    
VBIO        2050.6% 
• View Complete Report
   



Product Service News

BrainsWay’s Breakthrough FDA Clearance A New Hope in Adolescent Depression Treatment Amid Revenue Struggles

Published Thu, Nov 13 2025 12:05 PM UTC

In a significant advancement in the field of mental health treatment, BrainsWay Ltd has received FDA clearance for its Deep Transcranial Magnetic Stimulation (Deep TMS) technology as an adjunct therapy for Major Depressive Disorder (MDD) in adolescents aged 15 to 21. This pivotal endorsement marks Deep TMS as the first and only transcranial magnetic stimulation device author...
Product Service News

BrainsWay Pioneers New Frontiers in Mental Health Promising TMS Data for Alcohol Use Disorder and Significant E...

Published Thu, Dec 12 2024 1:00 PM UTC

In a noteworthy advancement for the field of mental health treatment, BrainsWay Ltd. (NASDAQ & TASE: BWAY), a prominent player in non-invasive brain disorder therapies, unveiled positive independent pilot data from a study conducted at Stanford University. This research evaluates an accelerated protocol using the company’s sophisticated Deep Transcranial Magnetic Stimulati...
Clinical Study

Efficacy of Deep Transcranial Magnetic Stimulation in Pain Management Feasibility Study Findings from BrainsWay Ltd

Published Wed, Nov 20 2024 1:00 PM UTC

: Emerging evidence suggests that Deep Transcranial Magnetic Stimulation (Deep TMS) may offer a promising alternative for managing pain symptoms, particularly in patients with comorbid mental health disorders. Recent feasibility data released by BrainsWay Ltd (NASDAQ: BWAY) reveals significant reductions in pain, anxiety, and depression symptoms associated with the treatme...
Product Service News

Global Reach and Innovative Horizons BrainsWay’s Strategic Expansion in Neurostimulation Technology

Published Wed, Oct 9 2024 11:30 AM UTC

BrainsWay Ltd. is charting an ambitious course as a leader in the realm of noninvasive neurostimulation treatments. With a strategic push to expand its presence in East Asia, complemented by a robust network growth in the Western United States, the company is not only broadening its geographical footprint but also reinforcing its significant contributions to mental health ...
Financing Agreement

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Published Mon, Sep 30 2024 11:30 AM UTC

BrainsWayns Strategic Expansion and Financial Maneuvering: A New Chapter in Mental Health CareIn a rapidly changing landscape where mental health issues dominate societal concerns, BrainsWay Ltd. is poised to solidify its position as a leader in innovative treatments. The company, recognized for its cutting-edge transcranial magnetic stimulation (TMS) technologies, has rece...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.01
Working Capital Ratio 3.73
Leverage Ratio (MRQ) 0.31
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 404,845
Net Income per Employee (TTM) 58,721
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.46

Profitability Ratios Current
Gross Margin (MRQ) 75.42 %
Operating Margin (MRQ) 8.28 %
Net Margin (MRQ) 14.5 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 1.75 %

Management Effectiveness Current
Return On Assets (TTM) 6.71 %
Return On Investment (TTM) 10.53 %
Return On Equity (TTM) 10.53 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.